Samir Mitragotri Ph.D.
Founder
Samir Mitragotri is a global thought leader in the field of drug delivery and biomaterials. He has 30 years of research and translational experience in developing innovative technologies for transdermal drug delivery. He is a Professor of Bioengineering at Harvard University and Wyss Institute, an author of more than 400 scientific publications and an inventor on more than 200 patents/patent applications. He has been elected to the National Academy of Engineering for development, clinical translation, and commercialization of transdermal drug delivery systems.
Samir is also an elected member of the National Academy of Medicine and National Academy of Inventors and a fellow of multiple scientific organizations including American Association of Advancement of Science, Biomedical Engineering Society, and American Association of Pharmaceutical Scientists. He received his B.S. in chemical engineering from the Institute of Chemical Technology, India and a Ph.D. in chemical engineering from the Massachusetts Institute of Technology.
Douglas Levinson Ph.D.
Founder, CEO
Doug Levinson is a science-driven, serial entrepreneur who’s created and led numerous successful life science companies. Prior to founding Fount Bio, Doug founded and served as CEO Cytrellis Biosystems, which developed an FDA-cleared, proprietary system for the aesthetic dermatology market; T2 Biosystems (TTOO), a commercial-stage diagnostics company based on nano technology; and YourBio Health, a company that develops safe and simple-to-use devices for blood collection and diagnostics. Doug served as a partner at Flagship Ventures where he was a member of the life sciences investment team. Prior to Flagship, Doug was a founding team member of TransForm Pharmaceuticals, serving on the management team until the company was acquired by J&J, and Millennium Pharmaceuticals (acquired by Takeda). Doug holds a Ph.D. in genetics from Harvard University.
Amrita Banerjee, Ph.D.
Principal Scientist
Dan Browne
Board Member
Dan Browne has more than 30 years of entrepreneurial and executive leadership experience in the healthcare industry. He has led the development of multiple innovative products that are leaders in their category, as well as critical business development and partnership activities. He is the co-founder and former president and chief executive officer of Revance Therapeutics, Inc. Dan brought the company from early-stage incubator in 2002 to a highly successful IPO in 2014. During the course of his tenure, he led clinical, regulatory/quality, finance and commercial operations. Prior roles include president and CEO of Neomend, president and CEO of Prograft Medical, and business leader at WL Gore & Associates, Inc. Since 2020, Dan has been a board member to AVAVA Medical and Rythera Therapeutics. Dan holds an MBA from Pepperdine Graziadio Business School and studied cell biology at the University of Hawaii.
Anthony Aiudi Pharm.D.
Board Member
Anthony Aiudi has been part of the investment team at Morningside Technology Advisory since 2020. He has experience providing operational and managerial oversight to early-stage biotechnology companies. Anthony serves on the boards of several biotechnology companies across a broad spectrum of therapeutic areas, including Neutrolis, Biothea, and Cyted. He has also facilitated company creation, completed multiple financings for private companies, and provided operational support for portfolio companies. Anthony completed a Fellowship in Clinical Research at Cubist Pharmaceuticals and Northeastern University, where he was also adjunct faculty. He later was a senior clinical research scientist at Merck & Co. From late 2015-2020, he was a director at Stealth BioTherapeutics, where he led the clinical development for numerous rare disease programs through their global Phase 3 program and supported the company through its IPO. Anthony received his Pharm.D. and MBA from the University of Rhode Island and an M.S. in finance from Northeastern University.
Justin Burns Ph.D.
Board Member
Justin Burns is a member of the investment team at Morningside where he evaluates new opportunities and supports company creation and financing for companies in the life sciences, Ag-Tech, and digital health fields. Additionally, Justin provides operational support and managerial oversight to portfolio companies and serves as a director on the boards of several biotechnology companies, including Pinteon Therapeutics and Prospective Research. Prior to joining Morningside, Justin was a director in the licensing and intellectual property office at Emory University where he negotiated and executed exclusive commercial licenses and institutional research collaborations. Additionally, he held primary responsibility for the university’s research, data, and clinical trial contracting. Prior to his tenure at Emory, Justin completed fellowships with the National Academies after receiving his Ph.D. in molecular biology and biochemistry from the Georgia Institute of Technology.
Dan Liu, Ph.D.
Research Scientist
Dhwani Kansal, Ph.D.
Research Scientist
Manoj Madhavan Ph.D.
Scientist
David Cavacini, CFO
Consultant
Andrew Kanach, Ph.D.
Scientist / Project Manager
Shuyang Zhang
Research Scientist